Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 1.0MB
Regulatory Filings
2026-04-29 English
Positive Regulatory Inspection Outcome for Phase 3 Trial 3 pages 320.5KB
Regulatory Filings Classification · 78% confidence The document is an ASX announcement by Recce Pharmaceuticals regarding the outcome of a routine regulatory inspection of a Phase 3 clinical trial site in Indonesia. It is not an AGM presentation, financial report, earnings release, M&A activity, or any other narrowly defined category. Instead, it is a general regulatory update filed with the exchange, fitting the fallback “Regulatory Filings (RNS)” category.
2026-04-20 English
Notification of cessation of securities - RCE 4 pages 14.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for RECCE PHARMACEUTICALS LTD. It provides specific information about securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options due to lapse of conditional rights. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about securities changes and does not constitute a full financial report or other specific filing type. The document length is 4260 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2026-04-14 English
Brazil Patent Granted for RECCE Anti-Infectives 3 pages 317.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the granting of a patent in Brazil for Recce Pharmaceuticals' anti-infective products. It details the patent specifics, market information, and company background. There is no financial data, no report attached or referenced as being published, no management or board changes, no earnings or interim report, and no regulatory certification. The content is a formal announcement of a patent grant, which fits best under a general regulatory announcement category rather than a financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters, and it is a standalone announcement, not a report or presentation.
2026-03-23 English
RCE Investor Webinar Presentation Deck 39 pages 2.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Recce Pharmaceuticals Ltd, dated March 2026, containing extensive company overview, management bios, clinical trial updates, product descriptions, and strategic outlook. It includes forward-looking statements, clinical program results, and detailed scientific and commercial information. The document is structured as a presentation with disclaimers and is intended for investors or stakeholders. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting result or capital update. The content and format align with an Investor Presentation (IP), which typically includes company strategy, clinical progress, management background, and market positioning. The document length (15,000 characters) and detailed content support this classification rather than a brief announcement or report publication notice.
2026-03-18 English
RCE Investor Webinar Presentation 1 page 257.3KB
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor webinar presentation by Recce Pharmaceuticals. It includes details about the event date, time, topics to be covered, and registration information. There is no actual financial data, report content, or detailed presentation material included in the text. The document is short (1346 characters) and serves to inform investors about the webinar event rather than providing the presentation itself. Therefore, it fits the category of an Investor Presentation announcement rather than a full report or transcript.
2026-03-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.